Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014 (2014), Article ID 781340, 8 pages
http://dx.doi.org/10.1155/2014/781340
Review Article

Hypofractionation in Prostate Cancer: Radiobiological Basis and Clinical Appliance

1Radiotherapy Unit, Department of Experimental and Clinical Biomedical Sciences, University of Florence, Largo Brambilla 3, 50134 Firenze, Italy
2Urology Unit, Department of Experimental and Clinical Medicine, University of Florence, 50134 Florence, Italy

Received 1 March 2014; Accepted 6 April 2014; Published 30 April 2014

Academic Editor: Giovanni Luca Gravina

Copyright © 2014 M. Mangoni et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Jemal, F. Bray, M. M. Center, J. Ferlay, E. Ward, and D. Forman, “Global cancer statistics,” CA: A Cancer Journal for Clinicians, vol. 61, no. 2, pp. 69–90, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. F. H. Schroder, J. Hugosson, M. J. Roobol et al., “Screening and prostate-cancer mortality in a randomized european study,” The New England Journal of Medicine, vol. 360, no. 13, pp. 1320–1328, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. D. A. Kuban, S. L. Tucker, L. Dong et al., “Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer,” International Journal of Radiation, Oncology, Biology Physics, vol. 70, no. 1, pp. 67–74, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. A. L. Zietman, K. Bae, J. D. Slater et al., “Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from Proton Radiation Oncology Group/American College Of Radiology 95-09,” Journal of Clinical Oncology, vol. 28, no. 7, pp. 1106–1111, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. H. R. Withers, “Biologic basis for altered fractionation schemes,” Cancer, vol. 55, supplement 9, pp. 2086–2095, 1985. View at Google Scholar · View at Scopus
  6. H. D. Thames Jr., H. R. Withers, L. J. Peters, and G. H. Fletcher, “Changes in early and late radiation responses with altered dose fractionation: implications for dose-survival relationships,” International Journal of Radiation, Oncology, Biology Physics, vol. 8, no. 2, pp. 219–226, 1982. View at Google Scholar · View at Scopus
  7. J. F. Fowler, “The linear-quadratic formula and progress in fractionated radiotherapy,” British Journal of Radiology, vol. 62, no. 740, pp. 679–694, 1989. View at Google Scholar · View at Scopus
  8. F. McKenna and S. Ahmad, “Isoeffect calculations with the linear quadratic and its extensions: an examination of model-dependent estimates at doses relevant to hypofractionation,” Journal of Medical Physics, vol. 36, no. 2, pp. 100–106, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. S. L. Tucker, H. D. Thames, J. M. Michalski et al., “Estimation of α/β for late rectal toxicity based on RTOG 94-06,” International Journal of Radiation, Oncology, Biology Physics, vol. 81, no. 2, pp. 600–605, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. D. J. Brenner and E. J. Hall, “Fractionation and protraction for radiotherapy of prostate carcinoma,” International Journal of Radiation, Oncology, Biology Physics, vol. 43, no. 5, pp. 1095–1101, 1999. View at Publisher · View at Google Scholar · View at Scopus
  11. D. J. Carlson, R. D. Stewart, X. A. Li, K. Jennings, J. Z. Wang, and M. Guerrero, “Comparison of in vitro and in vivoα/β ratios for prostate cancer,” Physics in Medicine and Biology, vol. 49, no. 19, pp. 4477–4491, 2004. View at Publisher · View at Google Scholar · View at Scopus
  12. J. P. Kirkpatrick, J. J. Meyer, and L. B. Marks, “The linear-quadratic model is inappropriate to model high dose per fraction effects in radiosurgery,” Seminars in Radiation Oncology, vol. 18, no. 4, pp. 240–243, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. J. M. Brown, D. J. Carlson, and D. J. Brenner, “The tumor radiobiology of SRS and SBRT: are more than the 5 Rs involved ?” International Journal of Radiation, Oncology, Biology Physics, vol. 88, no. 2, pp. 254–262, 2014. View at Publisher · View at Google Scholar
  14. H. R. Withers, “The four R's of radiotherapy,” in Advances in Radiation Biology, J. T. Lett and H. Adler, Eds., vol. 5, pp. 241–271, Academic Press, New York, NY, USA, 1975. View at Google Scholar
  15. J. Denekamp, “Changes in the rate of repopulation during multifraction irradiation of mouse skin,” British Journal of Radiology, vol. 46, no. 545, pp. 381–387, 1973. View at Google Scholar · View at Scopus
  16. J. F. Fowler, “Fractionated radiation therappy after Strandqvist,” Acta Radiologica Oncology, vol. 23, no. 4, pp. 209–216, 1984. View at Google Scholar · View at Scopus
  17. S. M. Bentzen and H. D. Thames, “Clinical evidence for tumor clonogen regeneration: interpretations of the data,” Radiotherapy & Oncology, vol. 22, no. 3, pp. 161–166, 1991. View at Publisher · View at Google Scholar · View at Scopus
  18. H. R. Whithers, J. M. Taylor, and B. Maciejewski, “The hazard of accelerated tumor clonogen repopulation during radiotherapy,” Acta Oncologica, vol. 27, no. 2, pp. 131–146, 1988. View at Google Scholar · View at Scopus
  19. J. Denekamp, “Cell kinetics and radiation biology,” International Journal of Radiation Biology and Related Studies in Physics, Chemistry, and Medicine, vol. 49, no. 2, pp. 357–380, 1986. View at Publisher · View at Google Scholar
  20. H. R. Withers, H. D. Thames, L. J. Peters et al., “Normal tissue radioresistance in clinical radiotherapy,” in Biological Bases and Clinical Implications of Tumor Radioresistance, G. H. Fletcher, C. Nervi, and H. R. Withers, Eds., Masson, New York, NY, USA, 1983. View at Google Scholar
  21. H. D. Thames Jr., H. R. Withers, L. J. Peters, and G. H. Fletcher, “Changes in early and late radiation responses with altered dose fractionation: implications for dose-survival relationships,” International Journal of Radiation, Oncology, Biology Physics, vol. 8, no. 2, pp. 219–226, 1982. View at Google Scholar · View at Scopus
  22. T. J. Whelan, D. H. Kim, and J. Sussman, “Clinical experience using hypofractionated radiation schedules in breast cancer,” Seminars in Radiation Oncology, vol. 18, no. 4, pp. 257–264, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. J. R. Owen, A. Ashton, J. M. Bliss et al., “Effect of radiotherapy fraction size on tumour control in patients with early-stage breast cancer after local tumour excision: long-term results of a randomised trial,” The Lancet Oncology, vol. 7, no. 6, pp. 467–471, 2006. View at Publisher · View at Google Scholar · View at Scopus
  24. J. F. Fowler, R. Chappell, and M. Ritter, “Is α/β for prostate tumors really low?” International Journal of Radiation, Oncology, Biology Physics, vol. 50, no. 4, pp. 1021–1031, 2001. View at Publisher · View at Google Scholar · View at Scopus
  25. R. Miralbell, S. A. Roberts, E. Zubizarreta, and J. H. Hendry, “Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: α/β = 1.4 (0.9–2.2) Gy,” International Journal of Radiation Oncology Biology Physics, vol. 82, no. 1, pp. e17–e24, 2012. View at Publisher · View at Google Scholar · View at Scopus
  26. J. Z. Wang, M. Guerrero, and X. A. Li, “How low is the α/β ratio for prostate cancer?” International Journal of Radiation Oncology Biology Physics, vol. 55, no. 1, pp. 194–203, 2003. View at Publisher · View at Google Scholar
  27. H. Kal and M. P. van Gellekom, “How low is the α/β ratio for prostate cancer?” International Journal of Radiation, Oncology, Biology Physics, vol. 57, no. 4, pp. 1116–1121, 2003. View at Publisher · View at Google Scholar · View at Scopus
  28. C. R. King and C. S. Mayo, “Is the prostate α/β ratio of 1.5 from Brenner and Hall a modeling artifact?” International Journal of Radiation, Oncology, Biology Physics, vol. 47, no. 2, pp. 536–539, 2000. View at Publisher · View at Google Scholar · View at Scopus
  29. P. Pedicini, L. Strigari, and M. Benassi, “Estimation of a self-consistent set of radiobiological parameters from hypofractionated versus standard radiation therapy of prostate cancer,” International Journal of Radiation, Oncology, Biology Physics, vol. 85, no. 5, pp. e231–e237, 2013. View at Publisher · View at Google Scholar
  30. N. G. Zaorsky, N. Ohri, T. N. Showalter, A. P. Dicker, and R. B. Den, “Systematic review of hypofractionated radiation therapy for prostate cancer,” Cancer Treatment Reviews, vol. 39, no. 7, pp. 728–736, 2013. View at Publisher · View at Google Scholar
  31. R. W. Lloyd-Davies, C. D. Collins, and A. V. Swan, “Carcinoma of prostate treated by radical external beam radiotherapy using hypofractionation. Twenty-two years' experience (1962–1984),” Urology, vol. 36, no. 2, pp. 107–111, 1990. View at Publisher · View at Google Scholar · View at Scopus
  32. C. D. Collins, R. W. Lloyd-Davies, and A. V. Swan, “Radical external beam radiotherapy for localised carcinoma of the prostate using a hypofractionation technique,” Clinical Oncology, vol. 3, no. 3, pp. 127–132, 1991. View at Google Scholar · View at Scopus
  33. H. Lukka, C. Hayter, J. A. Julian et al., “Randomized trial comparing two fractionation schedules for patients with localized prostate cancer,” Journal of Clinical Oncology, vol. 23, no. 25, pp. 6132–6138, 2005. View at Publisher · View at Google Scholar · View at Scopus
  34. E. E. Yeoh, R. H. Holloway, R. J. Fraser et al., “Hypofractionated versus conventionally fractionated radiation therapy for prostate carcinoma: updated results of a phase III randomized trial,” International Journal of Radiation, Oncology, Biology Physics, vol. 66, no. 4, pp. 1072–1083, 2006. View at Publisher · View at Google Scholar · View at Scopus
  35. E. E. Yeoh, R. J. Botten, J. Butters, A. C. di Matteo, R. H. Holloway, and J. Fowler, “Hypofractionated versus conventionally fractionated radiotherapy for prostate carcinoma: final results of phase III randomized trial,” International Journal of Radiation Oncology Biology Physics, vol. 81, no. 5, pp. 1271–1278, 2011. View at Publisher · View at Google Scholar · View at Scopus
  36. American Society for Therapeutic Radiology and Oncology Consensus Panel, “Consensus statement: guidelines for PSA following radiation therapy,” International Journal of Radiation Oncology Biology Physics, vol. 37, no. 5, pp. 1035–1041, 1997. View at Publisher · View at Google Scholar · View at Scopus
  37. M. C. Abramowitz, T. Li, M. K. Buyyounouski et al., “The phoenix definition of biochemical failure predicts for overall survival in patients with prostate cancer,” Cancer, vol. 112, no. 1, pp. 55–60, 2008. View at Publisher · View at Google Scholar · View at Scopus
  38. D. P. Dearnaley, E. Hall, D. Lawrence et al., “Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects,” British Journal of Cancer, vol. 92, no. 3, pp. 488–498, 2005. View at Publisher · View at Google Scholar · View at Scopus
  39. D. P. Dearnaley, M. R. Sydes, R. E. Langley et al., “The early toxicity of escalated versus standard dose conformal radiotherapy with neo-adjuvant androgen suppression for patients with localised prostate cancer: results from the MRC RT01 trial (ISRCTN47772397),” Radiotherapy & Oncology, vol. 83, no. 1, pp. 31–41, 2007. View at Publisher · View at Google Scholar · View at Scopus
  40. P. Kupelian, D. Kuban, H. Thames et al., “Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995,” International Journal of Radiation, Oncology, Biology Physics, vol. 61, no. 2, pp. 415–419, 2005. View at Publisher · View at Google Scholar · View at Scopus
  41. A. Pollack, G. K. Zagars, G. Starkschall et al., “Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial,” International Journal of Radiation, Oncology, Biology Physics, vol. 53, no. 5, pp. 1097–1105, 2002. View at Publisher · View at Google Scholar
  42. S. T. Peeters, W. D. Heemsbergen, P. C. M. Koper et al., “Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy,” Journal of Clinical Oncology, vol. 24, no. 13, pp. 1990–1996, 2006. View at Publisher · View at Google Scholar · View at Scopus
  43. M. J. Zelefsky, Y. Yamada, Z. Fuks et al., “Long-term results of conformal radiotherapy for prostate cancer: impact of dose escalation on biochemical tumor control and distant metastases-free survival outcomes,” International Journal of Radiation, Oncology, Biology Physics, vol. 71, no. 4, pp. 1028–1033, 2008. View at Publisher · View at Google Scholar · View at Scopus
  44. G. Arcangeli, B. Saracino, S. Gomellini et al., “A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high-risk prostate cancer,” International Journal of Radiation, Oncology, Biology Physics, vol. 78, no. 1, pp. 11–18, 2010. View at Publisher · View at Google Scholar
  45. G. Arcangeli, J. Fowler, S. Gomellini et al., “Acute and late toxicity in a randomized trial of conventional versus hypofractionated three-dimensional conformal radiotherapy for prostate cancer,” International Journal of Radiation, Oncology, Biology Physics, vol. 79, no. 4, pp. 1013–1021, 2011. View at Publisher · View at Google Scholar · View at Scopus
  46. S. Arcangeli, L. Strigari, S. Gomellini et al., “Updated results and patterns of failure in a randomized hypofractionation trial for high-risk prostate cancer,” International Journal of Radiation Oncology, Biology, Physics, vol. 84, no. 5, pp. 1172–1178, 2012. View at Publisher · View at Google Scholar · View at Scopus
  47. D. A. Kuban, G. M. Nogueras-Gonzalez, L. Hamblin et al., “Preliminary report of a randomized dose escalation trial for prostate cancer using hypofractionation,” International Journal of Radiation Oncology, Biology, Physics, vol. 78, no. 3, supplement, pp. S58–S59, 2010. View at Publisher · View at Google Scholar
  48. A. Pollack, G. Walker, E. M. Horwitz et al., “Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer,” Journal of Clinical Oncology, vol. 31, no. 31, pp. 3860–3868, 2013. View at Publisher · View at Google Scholar
  49. P. A. Kupelian, T. R. Willoughby, C. A. Reddy, E. A. Klein, and A. Mahadevan, “Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: cleveland clinic experience,” International Journal of Radiation, Oncology, Biology Physics, vol. 68, no. 5, pp. 1424–1430, 2007. View at Publisher · View at Google Scholar · View at Scopus
  50. D. Dearnaley, I. Syndikus, G. Sumo et al., “Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial,” The Lancet Oncology, vol. 13, no. 1, pp. 43–54, 2012. View at Publisher · View at Google Scholar · View at Scopus
  51. Y. Yoshioka, K. Konishi, R.-J. Oh et al., “High-dose-rate brachytherapy without external beam irradiation for locally advanced prostate cancer,” Radiotherapy & Oncology, vol. 80, no. 1, pp. 62–68, 2006. View at Publisher · View at Google Scholar · View at Scopus
  52. Y. Yoshioka, K. Konishi, I. Sumida et al., “Monotherapeutic high-dose-rate brachytherapy for prostate cancer: five-year results of an extreme hypofractionation regimen with 54 Gy in nine fractions,” International Journal of Radiation, Oncology, Biology Physics, vol. 80, no. 2, pp. 469–475, 2011. View at Publisher · View at Google Scholar · View at Scopus
  53. L. Schour, D. J. Demanes, G. A. Altieri, D. Brandt, M. Barnaba, and P. Skoolisariyaporn, “High dose rate monotherapy for prostate cancer,” International Journal of Radiation, Oncology, Biology Physics, vol. 63, supplement 1, p. S315, 2005. View at Google Scholar
  54. D. J. Demanes, A. A. Martinez, M. Ghilezan et al., “High-dose-rate monotherapy: safe and effective brachytherapy for patients with localized prostate cancer,” International Journal of Radiation, Oncology, Biology Physics, vol. 81, no. 5, pp. 1286–1292, 2011. View at Publisher · View at Google Scholar · View at Scopus
  55. C. Corner, A. M. Rojas, L. Bryant, P. Ostler, and P. Hoskin, “A phase II study of high-dose-rate afterloading brachytherapy as monotherapy for the treatment of localized prostate cancer,” International Journal of Radiation, Oncology, Biology Physics, vol. 72, no. 2, pp. 441–446, 2008. View at Publisher · View at Google Scholar · View at Scopus
  56. N. G. Zaorsky, M. T. Studenski, A. P. Dicker et al., “Stereotactic body radiation therapy for prostate cancer: is the technology ready to be the standard of care?” Cancer Treatment Reviews, vol. 39, no. 3, pp. 212–218, 2013. View at Publisher · View at Google Scholar
  57. B. L. Madsen, R. A. Hsi, H. T. Pham, J. F. Fowler, L. Esagui, and J. Corman, “Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: first clinical trial results,” International Journal of Radiation, Oncology, Biology Physics, vol. 67, no. 4, pp. 1099–1105, 2007. View at Publisher · View at Google Scholar · View at Scopus
  58. C. I. Tang, D. A. Loblaw, P. Cheung et al., “Phase I/II study of a five-fraction hypofractionated accelerated radiotherapy treatment for low-risk localized prostate cancer: early results of pHART3,” Clinical Oncology, vol. 20, no. 10, pp. 729–737, 2008. View at Publisher · View at Google Scholar · View at Scopus
  59. H. Quon, P. Cheung, A. Cesta et al., “Phase II study of a five-fraction hypofractionated accelerated radiotherapy treatment for low-risk localized prostate cancer: toxicity results of pHART3,” in Genitourinary Cancers Symposium, Orlando, Fla, USA, 2010.
  60. A. J. Katz, M. Santoro, F. DiBlasio et al., “Stereotactic body radiation therapy for low-, intermediate- and high-risk prostate cancer: disease control and quality of life,” International Journal of Radiation, Oncology, Biology Physics, vol. 81, no. 2, supplement, p. S100, 2011. View at Google Scholar
  61. A. J. Katz, M. Santoro, R. Ashley, F. Diblasio, and M. Witten, “Stereotactic body radiotherapy as boost for organ-confined prostate cancer,” Technology in Cancer Research and Treatment, vol. 9, no. 6, pp. 575–582, 2010. View at Google Scholar · View at Scopus
  62. D. E. Freeman and C. R. King, “Stereotactic body radiotherapy for low-risk prostate cancer: five-year outcomes,” Radiation Oncology, vol. 6, no. 1, article 3, 2011. View at Publisher · View at Google Scholar · View at Scopus
  63. C. R. King, J. D. Brooks, H. Gill, and J. C. Presti Jr., “Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer,” International Journal of Radiation, Oncology, Biology Physics, vol. 82, no. 2, pp. 877–882, 2012. View at Publisher · View at Google Scholar · View at Scopus
  64. N. C. Townsend, B. J. Huth, W. Ding et al., “Acute toxicity after cyberknife-delivered hypofractionated radiotherapy for treatment of prostate cancer,” American Journal of Clinical Oncology, vol. 34, no. 1, pp. 6–10, 2011. View at Publisher · View at Google Scholar · View at Scopus